Study to Evaluate the Safety and Efficacy of CHAM* for the Treatment of Diabetic Foot Ulcers

Phase 3

Terminated

• Conditions: Chronic Diabetic Foot Ulcers
• Interventions: Other: Control; Biological: CHAM

• Registration Number: NCT02571738
• Lead Sponsor: Osiris Therapeutics

Brief Summary

A Multicenter, Randomized, Single-Blind Study with an Open-Label Extension Option to Further Evaluate the Safety and Efficacy of Cryopreserved Human Amniotic Membrane for the Treatment of Chronic Diabetic Foot Ulcers

Detailed Description

Not available

Study Timeline

• Study Start: 2015-10
• Study First Submitted: 2015-10-06
• Study First Submitted QC: 2015-10-06
• Study First Posted: 2015-10-08
• Primary Completion: 2017-04
• Study Completion: 2017-06
• Status Verified: 2017-10
• Last Update Submitted: 2017-10-05
• Last Update Posted: 2017-10-06

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 108

Inclusion Criteria

1. Between 18 years and 80 years of age inclusive, as of the date of screening

2. Confirmed diagnosis of Type I or Type II Diabetes

3. An Index Ulcer defined as chronic (presence of wound for > 4 weeks), but not present for more than 52 weeks at the Screening Visit

4. Index Ulcer is located below the malleoli on the plantar or dorsal surface of the foot

5. The Index Ulcer is between 1 cm2 and 15 cm2, inclusive, at the Screening Visit

6. The Index Ulcer extends into the dermis or subcutaneous tissue without evidence of exposed muscle, tendon, bone, or joint capsule

7. Wound is free of necrotic debris

8. Patient has adequate circulation to the foot as documented by either:

   • Ankle Brachial Index (ABI) > 0.70 and < 1.30, or
   • In patients with non-compressible ankle vessels defined as an ABI ≥ 1.30, a Toe Brachial Index (TBI) ≥ 0.50, or
   • In patients with non-compressible ankle vessels defined as an ABI ≥ 1.30 and TBI cannot be performed (e.g., toe is absent, wounds are present, or site cannot perform a TBI), a Doppler waveform in the posterior tibial or dorsalis pedis arteries at the ankle consistent with adequate flow in the foot (biphasic or triphasic) and other diagnostic confirmation of adequate flow (e.g., duplex imaging, normal pulse volume recording [PVR] testing).

Exclusion Criteria

1. Index Ulcer is of non-diabetic pathophysiology
2. Gangrene is present on any part of the affected foot
3. Index Ulcer is over an active Charcot deformity
4. The longest dimension of the Index Ulcer exceeds 5 cm at the Baseline Visit
5. Patient is currently receiving dialysis or planning to go on dialysis
6. Patient has had 2 or more previous disease-related amputations of the lower extremities
7. Patient has a glycated hemoglobin A1c (HbA1c) level of >10%
8. Chronic oral steroid use >7.5 mg daily for longer than 3 months at the time of screening
9. Patient is receiving IV corticosteroids, immunosuppressive or cytotoxic agents at the time of screening
10. Requiring intravenous (IV) antibiotics to treat the index wound infection at the time of screening
11. Patient has an ulcer within 5 cm of the Index Ulcer identified for study consideration
12. Patient is Human Immunodeficiency Virus (HIV) positive or has Acquired Immune Deficiency Syndrome (AIDS)
13. Current evidence of cellulitis, or other evidence of infection including fever or pus drainage from the wound site
14. Current evidence of osteomyelitis or history of osteomyelitis within 30 days of screening
15. Patient has active malignancy other than non-melanoma skin cancer
16. Patient's Index Ulcer has decreased by ≥20% during 1-week screening period
17. Patient's random blood sugar is >350 mg/dl at screening
18. Patient has untreated alcohol or substance abuse at the time of screening
19. Pregnant women and women who are breastfeeding
20. Patient is currently enrolled or participated in another investigational device, drug, or biological trial within 30 days of screening
21. Patient has had within the last 30 days, or is currently undergoing, or is planning for wound treatments with growth factors, living skin, dermal substitutes or other advanced biological therapies
22. Patient is an employee, or an immediate family member of an employee, of the sponsor company or site research staff conducting the study
23. Patients who have already been randomized in Protocol 303 at any center may not be considered for screening or for re-entry into the trial at any center, even after the end of their follow-up period
24. Patients with a history of poor compliance, or an unwillingness or inability to adhere to the requirements of the protocol.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Control	Control	Standard of Care
CHAM	CHAM	Cryopreserved Human Amniotic Membrane

Primary Outcome Measures

Name	Time	Method
Complete closure of the index wound, defined as 100% re-epithelialization as determined by the Investigator, by the End of Single-Blind Treatment Visit with follow-up confirmation of continued closure at 2 consecutive study visits 2 weeks apart	Up to 112 days after Baseline Visit

Secondary Outcome Measures

Name	Time	Method
Complete index wound closure by the End of Single-Blind Treatment Visit as defined by 100% re-epithelialization, as determined by the Investigator.	Up to 84 days after Baseline Visit
Time to initial wound closure among patients that receive CHAM versus those that receive control as measured by Kaplan-Meier analysis.	Up to 84 days after Baseline Visit
Number of applications of CHAM versus control	Up to 77 days after Baseline
Percentage of patients who achieve complete wound closure, defined as 100% re-epithelialization as determined by the Investigator, who participate in the Open-Label Treatment Phase	Up to 91 days after Single-Blind Treatment Phase
Proportion of patients receiving CHAM that achieve a 50% reduction or greater in wound size by Day 28 (± 3 days) versus those that receive control.	Up to 28 days after Baseline

Trial Locations

Locations (17)

Center for Clinical Research; 🇺🇸 San Francisco, California, United States

Barry University Clinical Research; 🇺🇸 North Miami Beach, Florida, United States

MedStar Georgetown University Hospital; 🇺🇸 Washington, D.C., District of Columbia, United States

Stanford University; 🇺🇸 Stanford, California, United States

Ocean County Foot & Ankle Surgical Associates; 🇺🇸 Toms River, New Jersey, United States

Temple University; 🇺🇸 Philadelphia, Pennsylvania, United States

Spartanburg Regional Healthcare System; 🇺🇸 Spartanburg, South Carolina, United States

North Texas Podiatric Medicine and Surgery Associates; 🇺🇸 Dallas, Texas, United States

ILD Research Center; 🇺🇸 Carlsbad, California, United States

Cleveland Clinic; 🇺🇸 Cleveland, Ohio, United States

SAVAHCS; 🇺🇸 Tucson, Arizona, United States

NSLIJHS; 🇺🇸 Lake Success, New York, United States

SSH; 🇺🇸 South Weymouth, Massachusetts, United States

University Orthopedics; 🇺🇸 Altoona, Pennsylvania, United States

Texas Gulf Coast Medical Group; 🇺🇸 Webster, Texas, United States

UNC; 🇺🇸 Chapel Hill, North Carolina, United States

Duke University; 🇺🇸 Durham, North Carolina, United States